Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Derma Sciences: Close to Upgrading (DSCI, $4.54)

Investment Perspective

With the failure of its biotechnology drug candidate aclerastide, Derma Sciences is abandoning drug development efforts. The Company…
Read more…

Derma Sciences: Second Quarter Results Were Disappointing; Going From a Buy to a Hold (DSCI, $9.72)

Derma Sciences released second quarter results this morning and this is my quick take. I will have a more detailed…
Read more…

Derma Sciences: Highlights of the June 17th Analystsí Meeting (DSCI, Buy, $11.07, Free content)

Price Target Thinking

In my initiation report of January 31, 2014, I argued for a 2018 price target of $20 to…
Read more…

Derma Sciences: An Update and Re-iteration of Buy Recommendation (DSCI, Buy $9.50, For Paid Subscribers)

Investment Perspective in Brief

I am re-iterating my Buy recommendation on Derma Sciences (DSCI) as I believe that it presents an…
Read more…

Ed Quilty, CEO of Derma Sciences, Outlines His Strategy to Build the Premier Wound Healing Company (DSCI, $12.00)

Investment Thesis

I published an extensive report on Derma Sciences (DSCI) on January 31, 2014 in which I recommended purchase. I…
Read more…

Derma Sciences: An In-Depth Look at An Emerging Growth Stock (DSCI, $12.77) (Subscribers Only)

Investment Perspective in Brief

Derma Sciences presents an unusual and attractive biotechnology investment situation. We are all aware of the binary…
Read more…